(Q34984040)

5 August 2017

1 reference

title

Fibrosis and disease progression in hepatitis C. (English)

1 reference

5 August 2017

1

Patrick Marcellin

1 reference

5 August 2017

Tarik Asselah

2

1 reference

PubMed ID

12407576

5 August 2017

Nathalie Boyer

series ordinal

3

1 reference

PubMed ID

12407576

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

5 August 2017

1 reference

5 August 2017

36

1 reference

5 August 2017

S47-56

1 reference

5 August 2017

5 Suppl 1

1 reference

Matrix as a modulator of hepatic fibrogenesis

5 August 2017

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Histopathology of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

The cellular origin of extracellular matrix constituents

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Transforming growth factor beta 1: in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Histological features predictive of liver fibrosis in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Expression of connective tissue growth factor in experimental rat and human liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Impact of alcohol on the histological and clinical progression of hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Detection and quantitation of serum HCV-RNA by branched DNA amplification in anti-HCV positive blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Quantitation of hepatic hepatitis C virus RNA in patients with chronic hepatitis C. Relationship with severity of disease, viral genotype and response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Hepatitis C: the clinical spectrum of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Hypervariable region 1 quasispecies in hepatitis C virus genotypes 1b and 3 infected patients with normal and abnormal alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Chronic hepatitis C and superimposed nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

The long-term pathological evolution of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36993

21 January 2018

Identifiers

DOI

10.1053/JHEP.2002.36993

1 reference

5 August 2017

1 reference

PubMed ID

12407576